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Abstract
Background: The Freelite system for nephelometric or tur-
bidimetric measurement of serum free light chains (FLCs)
has been available since 2001. It has been valuable for the
management of patients with oligosecretory myeloma, light
chain myeloma and AL amyloidosis. However, there are sev-
eral limitations of the method. The goal of this study was to
evaluate the analytical performance of the FLC assay.
Methods: Titrated controls and clinical serum specimens
were used to determine precision and post-dilution recovery.
Results: As reported elsewhere, we found that the assay had
several limitations, including poor post-dilution linearity and
overestimation by nephelometry.
Conclusions: These data demonstrate that the results of the
FLC assay must be interpreted jointly by the clinician and
the biologist, taking into account the individual patient’s clin-
ical and biological characteristics.
Clin Chem Lab Med 2010;48:73–9.
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Introduction
The Freelite assay from The Binding Site Ltd., available
since 2001, can be used to determine the concentrations of
k and l free light chains (FLCs). Its use is recommended by
the International Myeloma Group for the diagnosis and fol-
low-up of oligosecretory myeloma (1) and AL amyloidosis
(2). The results have prognostic value at the time of diag-
nosis of symptomatic myeloma (3), indolent myeloma (4)
and monoclonal gammapathy of undetermined significance
(5). However, prospective studies are needed to determine
the precise role of the FLC assay in these pathologies.
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Serum FLCs could eventually replace the need for assess-
ment of Bence-Jones (BJ) proteinuria during the initial inves-
tigation and follow-up of monoclonal gammapathies (6).
Indeed, analysis of urine has a number of drawbacks. In
particular, it is highly dependent on renal glomerular and
tubular function. In addition, BJ proteinuria requires a 24-h
urine sample. Finally, quantification of the band observed
following electrophoresis or immunofixation of urinary pro-
teins is often difficult and imprecise (7).
The k and l FLC assay can be used on several types of
automated analyzers and has been adopted for use in many
laboratories worldwide. However, the results can be difficult
to interpret. In particular, the lack of post-dilution linearity
carries a risk of under- or overestimation. The goal of this
study was to evaluate the analytical characteristics of the
FLC assay, especially the influence of sample dilution, and
compare our results to those reported previously.
Materials and methods
Samples
Stored serum and urine samples from patients attending Rennes
University Hospital (France) for diagnosis or monitoring of mono-
clonal gammapathies were used for this study. Samples were
obtained following routine analysis by the biochemistry laboratory
with measurement of the k/l ratio. During the study, we also used
k and l quality control material provided by the manufacturer.
Serum FLC analysis
Serum FLCs were analyzed with the Dade Behring BNII analyzer
(Siemens Healthcare Diagnostics, Marburg, Germany) using neph-
elometry. We used several batches of Freelite commercial reagents
(The Binding Site Ltd., Birmingham, UK), and k and l quality
control material. Serum and control specimens were analyzed
according to the manufacturer’s instructions (8, 9).
Precision of k and l FLC assay on the Dade Behring BNII
Reproducibility was estimated from results obtained with controls
in successive runs. At the laboratory of biochemistry of Pontchaillou
University Hospital (Rennes, France), two different concentrations
of controls were analyzed at the beginning of each run and after
each calibration. Between January 2007 and March 2008, measure-
ments were performed each week and three different batches of
reagents were used for both the k FLC and l FLC assay. Coeffi-
cients of variation were calculated after repeated measurements of
k and l quality control material with each of the three different
reagent batches.
To assess repeatability, three clinical serum samples were chosen
that had low (l FLC), medium (k and l FLC) and high (k FLC)
concentrations of free k and/or l light chains. Coefficients of var-
iation were calculated from the results of 20 consecutive runs. To
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Table 2 Estimation of reproducibility.
1st control batch 2nd control batch 3rd control batch
k (21/01/07– l (12/01/07– k (13/04/07– l (16/04/07– k (09/11/07– l (26/10/07–
06/04/07) 30/03/07) 02/11/07) 19/10/07) 28/03/08) 28/03/08)
Level 1 Level 2 Level 1 Level 2 Level 1 Level 2 Level 1 Level 2 Level 1 Level 2 Level 1 Level 2
Mean, mg/L 16.28 31.72 26.11 58.32 16.41 28.71 28.75 56.89 14.14 25.54 27.53 56.84
SD 1.25 1.63 1.27 2.00 1.26 1.52 2.56 3.23 1.08 1.73 2.34 2.42
Coefficient of 7.68 5.14 4.85 3.44 7.67 5.31 8.91 5.67 7.67 6.76 8.49 4.25
variation, %
Target, mg/L 16.20 31.00 27.20 59.80 16.50 29.80 29.90 56.90 13.60 27.50 27.70 55.60
Two different concentrations of control were analyzed at the beginning of each run and after each calibration. Between January 2007 and
March 2008, runs were performed each week and three different batches of controls were used for both k and l FLC assays.
Table 1 Dilution ranges for FLC immunoassay on BNII reported
by the manufacturer (The Binding Site Ltd).
Dilution Dilution ranges Dilution ranges
l FLC, mg/L k FLC, mg/L







verify the precision between two runs, we also chose, at random,
seven other serum samples. The deviation between two runs, using
the same dilution, was calculated.
Study of post-dilution recovery The dilution ranges suggested
by the manufacturer overlap, indicating that, in theory, a given
serum can be assayed at several different dilutions (Table 1) to
obtain the same result. Using the six sample dilutions available on
the BNII, the FLC working range extends from 0.41 to 20,800
mg/L for l FLCs and from 0.3 to 15,200 mg/L for k FLCs.
To compare the results obtained for a given sample at different
dilutions, 12 serum and urine samples were analyzed along with a
pool of patient serum with a final k FLC concentration of 180
mg/L following serial two-fold dilutions. To identify factors poten-
tially responsible for non-agreement between results obtained at dif-
ferent dilutions of the same sample, controls containing known
concentrations were measured using the different possible dilutions.
Results
Precision of the k FLC and l FLC assay
Reproducibility was estimated from the results obtained with
controls in successive runs. The coefficients of variation for
the controls ranged between 5.14% and 7.68% for k FLCs,
and between 3.44% and 8.91% for l FLCs. The coefficients
of variation for k and l controls are shown in Table 2.
Reproducibality studies using three serum samples showed
coefficients of variation of 6.47% (l) and 6.45% (k) at the
standard 1/100 dilution. Coefficients of variation were 3.78%
for samples with very high k concentrations (dilution
1/8000), and 6.06% for low l concentrations (dilution 1/20).
The precision between two runs, using seven other clinical
serum samples obtained from routine samples from the
laboratory, was also determined. The maximal difference
between two measurements was 17.90% for k FLC and
10.05% for l FLC.
The Binding Site stipulates that control results are valid if
they are within "20% of the indicated target values. All the
results of repeatability and reproducibility were within the
maximal accepted variation for controls, suggesting that the
FLC assay using the BNII analyzer is sufficiently reliable.
Study of post-dilution recovery
Figure 1 shows the results of the k FLC assay in a serial
two-fold diluted pool of serum, with a theoretical starting
concentration of k FLC of 180 mg/L. The difference between
the observed and theoretical concentrations ranged from
–7.8% to q28.4%. Linearity was good at the different con-
centrations with the BNII analyzer. The correlation coef-
ficients were 0.9982, 0.9966, 0.9979 and 0.9996 for the 1/5,
1/20, 1/100 and 1/400 dilutions, respectively. It can also be
noted that for each theoretical concentration, the observed
concentration increased with the dilution factor. Also, dif-
ference between the observed and theoretical concentrations
exceeded 20% for two of eight samples.
To further study post-dilution recovery, 12 clinical serum
and urine samples were also analyzed. Based on the manu-
facturer’s overlapping working ranges, two or three dilutions
were possible for some samples and the results are shown in
Table 3.
Large differences were observed with low concentrations
of FLC (e.g., dilution 1/5, 1/20, 1/100: patients 3 and 12 for
l FLC). In contrast, for high concentrations of FLC (e.g.,
dilutions 1/400, 1/2000 and 1/8000: patient 4 for l FLC,
patient 1 for k FLC) the differences were less important. Few
such differences were seen with urine samples (patients 8
and 10). In addition, the observed differences between dilu-
tions of samples of similar concentrations were highly vari-
able from patient to patient (e.g., patients 1 and 9 for l FLC)
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Figure 1 Difference between the observed and theoretical concentrations in a serial two-fold diluted pool of serum (theoretical starting
concentration of k FLCs180 mg/L).
(A) Observed concentration according to the theoretical concentration of k FLC and working dilutions. The percentages correspond to the
calculated deviation compared to the theoretical concentration. (B) Deviation compared to the theoretical concentration and working dilution.
and difficult to predict. This issue could pose a problem for
interpreting results for some patients, as these discrepancies
could lead to an erroneous conclusion that the k/l ratio is
abnormal, when in fact the ratio is normal.
To identify potential factors responsible for the discrep-
ancies observed with the same sample assayed at different
dilutions, controls containing known concentrations were
assayed at the different possible dilutions. The results are
shown in Table 4. The observed differences, ranging from
–9.93% to q2.58%, were far smaller with the protein-free
controls and with the protein-poor urine samples compared
with serum. The problems observed with serum are probably
due to interference from matrix effects at low dilutions, pos-
sibly owing to the high protein content of serum. However,
other factors may be responsible for the discrepant results
observed at different dilutions.
Risk of overestimation
During our study, we observed the case of a patient moni-
tored for myeloma with a k FLC component. Electrophoresis
and serum protein immunofixation revealed the presence of
two monoclonal l FLCs migrating with the gammaglobulins
(data not shown). During follow-up, the FLC assay overes-
timated concentrations on two occasions (respectively 19,900
and 12,700 mg/L by nephelemetry, 5000 and 7300 mg/L by
electrophoresis). Values obtained with the Freelite method
in these patients did not correspond with the actual concen-
trations obtained by integration of the electrophoretic profile.
Discussion
Analytical performance of FLC assay
The FLC assay can detect a monoclonal component in cer-
tain situations where previously it was impossible. Thus, this
test makes an important contribution to patient management
in such cases. However, the FLC assay has several
limitations.
We identified a number of practical problems, confirming
data published elsewhere. Many of these issues are common
to all new immunoassays, but they are aggravated by the fact
that there is only one commercial reagent and no internatio-
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Table 3 FLC concentrations at different dilutions on the BNII for serum and urine samples.
Patients FLC l FLC k
Dilution Concentration, Recovery, Dilution Concentration, Recovery,
mg/L % mg/L %
1 Serum 100 9.77 197.4 2000 213 130.7
20 9.18 185.5 400 200 122.7
5 4.95 100 100 163 100
2 Serum 100 13.3 139 100 11.6 210.9
20 9.57 100 20 5.5 100
3 Serum 100 9.5 372 100 9.5 224.60
20 5.9 232.3 20 4.23 100
5 2.54 100
4 Serum 40,000 13,300 74.3 100 18.3 205.2
8000 17,900 100 20 8.92 100
5 Serum 100 11.9 255.9 100 15.5 118.3
20 7.28 156.6 20 13.1 100
5 4.65 100
6 Serum 400 45.2 168.7 100 11.3 200.7
100 44.2 164.9 20 5.63 100
20 26.8 100
7 Serum 100 10.5 160.6 100 15.4 181.2
20 14.2 217.1 20 8.5 100
5 6.54 100
8 Urine 8000 2090 78.3 100 16.3 87.2
2000 2670 100 20 18.7 100
9 Serum 100 17.8 327.8 100 50.8 196.1
20 11 202.6 20 25.9 100
5 5.43 100
10 Urine 100 8.42 73.9 400 66.4 138
20 11.4 100 100 48.1 100
11 Serum 100 16.8 158.5 100 15 175.4
20 10.6 100 20 8.55 100
12 Serum 100 10.1 381.1 100 13.5 230.4
20 6.44 243 20 5.86 100
5 2.65 100
The results obtained at the lowest dilution serve as basis (100%) for the calculation of percent recovery.
Table 4 FLC concentrations for k and l controls, analyzed at
several dilutions.
Controls Target, Dilution Concentration, Deviation,
mg/L mg/L %
l low 27.2 100 24.5 –9.93
20 25.8 –5.15
l high 59.8 100 58.6 –2.01
400 57.7 –3.51
k low 16.2 100 15.3 –5.56
20 16.3 0.62
k high 31 100 29.4 –5.16
400 31.8 2.58
nal standard. Clinicians and biologists must be aware of these
limitations if they are to avoid misinterpreting results.
Effects of serum dilution on the FLC assay results
Analysis of several serum samples on the BNII device
showed poor post-dilution linearity, with the observed values
increasing consistently with the dilution factor. The discrep-
ancies observed for a given sample measured at several dilu-
tions were highly variable from patient to patient, leading to
the risk of over- or underestimation of FLC concentrations.
Indeed, the dilution chosen for a given sample (based on the
patient’s historical values) is not always optimal, and the
working ranges provided by the manufacturer for different
dilutions overlap. This means that it is not always necessary
to re-run the sample at a higher or lower dilution. To mini-
mize the risk of error, laboratories using the Freelite meth-
od should use non-overlapping working ranges for each
dilution. Table 5 shows the non-overlapping working ranges
used in our laboratory. Another way to limit the risk of error
would be to use the starting dilution recommended by the
manufacturer, i.e., 1/100, without taking into account the
patient’s historical values. Unfortunately, this is a costly
option.
Similar conflicts between different dilutions of a given
sample were also reported in 2007 with the Immage Protein
System (Beckman Coulter Inc., Fullerton, CA, USA) (10).
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Table 5 Non-overlapping working ranges used in the laboratory
of biochemistry of Pontchaillou hospital (Rennes, France) for the
FLC immunoassay.
Dilution Dilution range Dilution range







In this study, the analysis of several dilutions of serum from
16 patients with monoclonal or polyclonal FLCs showed a
rise in the observed values as the dilution factor increased,
again creating a risk of over- or underestimation. Several
factors may explain these discrepancies between different
dilutions, as shown by our comparison of patient serum and
urine samples and titrated control samples. Our results show
a matrix effect with serum, the high protein concentration in
the reaction mixture possibly interfering with the antigen/
antibody reaction at low dilutions.
In their 2007 study, Tate et al. focused not on the influence
of the reaction medium, but instead on the nature of the FLC
participating in the immunochemical reaction. Comparison
of the responses obtained with samples containing polyclonal
FLC and samples containing monoclonal FLC showed that
the results varied when the samples were diluted. Post-dilu-
tion linearity was not as good for monoclonal FLC compared
with FLC, the latter behaving more like the calibrator which
is composed of polyclonal FLC. This might occur because
monoclonal FLC can recognize only one antibody species
among the polyclonal antibodies constituting the assay re-
agent, leading to antigen-to-antibody excess. Thus, for a
given amount of polyclonal reagent, antigen excess occurs
at lower concentrations with monoclonal FLCs than with
polyclonal FLCs. In addition, the differences were more
marked with k FLC compared with l FLC (10). Another
study, published in 1991, described problems of post-dilution
linearity with a monoclonal FLC assay (11).
Risk of overestimation In our study, we observed in a
myeloma patient a case of overestimation of the FLC con-
centration measured with nephelometry compared to results
obtained by integration of the electrophoretic profile. Poly-
merization of intact immunoglobulins (Igs), especially IgM
and IgA, is a frequent phenomenon and hinders their quan-
tification. Similarly, polymerization of FLCs can sometimes
lead to overestimation, as described in the literature (12–15).
It has been shown that FLCs can exist in multimeric forms,
in addition to their classical presentation as k FLC monomers
and l FLC dimers (14, 16). Moreover, complex formation
has been reported between a1-antitrypsin and k FLC, leading
to overestimation (17). In 2002, Abraham et al. described a
case of monoclonal l FLC overestimation by nephelometry,
owing to the presence of trimolecular aggregates composed
of three l FLC dimers (14). Likewise, urine assays often
give values far above the urine total protein concentration
(12).
Influence of the reagent batch on FLC assay results
Another study published by Tate in 2007 described signifi-
cant variability according to the reagent batch (10). This
means that the results obtained for a given patient monitored
for several years will be difficult to interpret, as several dif-
ferent reagent batches will inevitably be used. Clinicians
must be aware that variations in the k/l ratio can occur inde-
pendent of any spontaneous or treatment-induced changes in
disease. In addition, in a laboratory like ours where ;30
FLC assays are performed each week to primarily monitor
patients with hematological disorders, ideally a frozen ali-
quot of each patient’s previous serum sample should be re-
tested at the same time as the latest sample in order to
compensate for inter-batch variability, but this approach is
difficult due to issues of cost and storage and storage of
samples.
A case of ‘‘non-reaction’’ with several reagent batches of
the k FLC assay was noted in the study by Tate et al. involv-
ing a 70-year-old patient with k FLC multiple myeloma. The
reason why the monoclonal k FLC did not react with several
reagent batches was not identified. This first reported case
of ‘‘non-reaction’’ in a patient with a monoclonal k FLC
clearly shows that polyclonal reagents may not recognize all
k or l FLCs (whether monoclonal or polyclonal), owing to
their marked structural diversity (10).
Influence of the choice of analyzer on the results of
FLC assay Pairwise comparisons of automated analyzers
for FLC assay have been published. In 2003, Tate et al. (12)
compared the BN ProSpec (Siemens Healthcare Diagnos-
tics, Marburg, Germany) with the Immage Protein System.
The correlation study used serum from 37 patients. With low
values of k FLC and l FLC (3.5–19 mg/L and 3.7–26
mg/L, respectively), the corresponding correlation coeffi-
cients were 0.81 and 0.87. With higher values of k and l
FLCs (20–168 mg/L and 29–100 mg/L, respectively), the
corresponding correlation coefficients were better (0.95 and
0.96). In a study published by Pattenden et al. (18) compar-
ing serum FLC values obtained with the Dade Behring
BNII and the Olympus AU400 (Olympus Diagnostic Sys-
tems, Hamburg, Germany) from 112 patients, higher values
were obtained with the BNII device than with the AU400,
with the difference being more marked for l FLCs. Thus,
although the recommended reference ranges are the same for
all analyzers (18), the results of Tate and Pattenden show
that reference ranges must be established specifically for
each device.
The divergent results obtained with different analyzers
may be due in part to the use of nephelometry with some
devices (BNII, BN ProSpec, and Immage) and turbi-
dimetry on others (Olympus AU400). However, Tate et al.
also reported that two analyzers using the same detection
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method (nephelometry) could give different results, showing
that other factors contribute to this variability (12).
Risk of cross-reactions with intact Ig If the sample con-
tains intact Igs, with more bound light chains compared with
FLC, the reliability of the results will depend on the speci-
ficity of the antiserum. The non-specificity according to the
manufacturer is -0.4%, which, as pointed out by Nakano et
al., raises uncertainties, particularly for FLC k (19).
Practical implications for routine FLC assay
This study of the analytical performance of FLC assay con-
firms certain limitations of this method. Laboratory staff and
clinicians must be aware of the risk of over- or underesti-
mation, depending on the sample dilution and the use of
different reagent batches or analyzers, as well as of the risk
of reaction failure with some monoclonal FLCs. Indeed, this
variability can lead to major errors in measurement of k or
l FLC concentrations and the ratio. If these limitations are
not taken into account, they can lead to an incorrect diag-
nosis or misjudgment of the response to treatment. FLCs,
being the only marker available to monitor changes in oli-
gosecretory and non-secretory multiple myeloma and AL
amyloidosis, must have results that are as reproducible as
possible.
To minimize the risk of error, we recommend the
following:
• Non-overlapping working ranges should be used for each
dilution, thus reducing the imprecision due to poor post-
dilution linearity (Table 5). A sample must be systema-
tically re-run at a lower or higher dilution if the result
does not fall between these predefined limits.
• Ideally, local reference ranges should be established in
each laboratory using the Freelite technique. Indeed,
several studies have shown that significantly different
results may be obtained with different analyzers.
• For a given patient, all k and l FLC measurements should
ideally be performed in the same laboratory with the same
analyzer, leaving only the problem of inter-batch
variability.
• It is recommended that variations in serum FLC concen-
tration of -50% should not be considered as proof of
disease progression or of a response to treatment in
patients with AL amyloidsis (20) or multiple myeloma
(4).
• Dialogue between the biologist and clinician is essential
to ensure optimal assay conditions and interpretation. The
biologist must be provided with clinical information at
the time the sample is received, as knowledge of the dis-
ease and ongoing treatments will help to select the best
assay dilutions. This information will help limit the num-
ber of reruns and yield the most precise result possible.
For example, a higher dilution will be used initially if the
patient has signs of myeloma relapse. In turn, the biolo-
gist must inform the clinician of the analytical limits of
the assay in order to ensure that the results are interpreted
correctly, in conjunction with the patient’s clinical char-
acteristics. Given the high variability observed with low
dilutions, clinicians should be advised to ignore variations
in the k/l ratio in patients with below normal FLC
concentrations.
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